On October 13, 2025, CERo Therapeutics announced the completion of the first cohort of its Phase 1/1b trial of CER‑1236 in acute myeloid leukemia. The cohort, which included three patients, demonstrated no dose‑limiting toxicities and robust in‑vivo cell expansion consistent with preclinical expectations.
The Dose Escalation Safety Committee approved initiation of Cohort 2, allowing a fourth patient to receive an increased starting dose pending regulatory approval. The company also plans an additional infusion for the second subject of Cohort 1 based on encouraging pharmacokinetic data.
CERo clarified that it is not currently seeking partnerships or a sale and remains focused on advancing the dose‑finding study. This milestone moves the program toward establishing a recommended Phase 2 dose and supports the company’s strategy to develop its CER‑T platform for AML.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.